Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Yoshihara, Daisuke ^a   Kugita, Masanori ^a   Sasaki, Mai ^a   Horie, Shigeo ^b   Nakanishi, Koichi ^c   Abe, Takaaki ^d   Aukema, Harold M ^e   Yamaguchi, Tamio ^e   Nagao, Shizuko ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; KI 67 ANTIGEN; NITROGEN; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; FIBROSING ALVEOLITIS; HEPATIC FIBROSIS INDEX; HEPATOBILIARY PARAMETERS; KIDNEY POLYCYSTIC DISEASE; LIVER FIBROSIS; LIVER PROTECTION; LIVER WEIGHT; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL;

ANGIOTENSIN II; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CELL PROLIFERATION; CYSTS; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEPATOCYTES; HUMANS; KIDNEY FUNCTION TESTS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84891957093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081480     Document Type: Article

References (43)

1. Harris PC, Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60: 321-337.
2. Grantham JJ, Mulamalla S, Swenson-Fields KI (2011) Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7: 556-566.
3. Sweeney WE Jr, Avner ED (2011) Diagnosis and management of childhood polycystic kidney disease. Pediatr Nephrol 26: 675-692.
4. Turkbey B, Ocak I, Daryanani K, Font-Montgomery E, Lukose L, et al. (2009) Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF). Pediatr Radiol 39: 100-111.
5. Gunay-Aygun M, Avner ED, Bacallao RL, Choyke PL, Flynn JT, et al. (2006) Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr 149: 159-164. (Pubitemid 44144487)
6. Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman Gerstein M, Piwnica-Worms K, et al. (2013) Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology 144: 112-121 e112.
7. Goto M, Hoxha N, Osman R, Dell KM (2010) The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease. Pediatr Nephrol 25: 2449-2457.
8. Doggrell SA (2004) Telmisartan - killing two birds with one stone. Expert Opin Pharmacother 5: 2397-2400. (Pubitemid 39489992)
9. Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S (2008) PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res 2008: 658520.
10. Liu C, Zhang Y, Yuan L, Fu L, Mei C (2013) Rosiglitazone inhibits insulin-like growth factor1-induced polycystic kidney disease cell growth and p70S6 kinase activation. Mol Med Rep. In press.
11. Dekkers JF, van der Ent CK, Kalkhoven E, Beekman JM (2012) PPARgamma as a therapeutic target in cystic fibrosis. Trends Mol Med 18: 283-291.
12. Fouad AA, Al-Mulhim AS, Jresat I (2012) Telmisartan treatment attenuates arsenic-induced hepatotoxicity in mice. Toxicology 300: 149-157.
13. Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I (2007) Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 364: 801-807. (Pubitemid 350103697)
14. Yoshihara D, Kurahashi H, Morita M, Kugita M, Hiki Y, et al. (2011) PPARgamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 300: F465-474.
15. Yoshihara D, Kugita M, Yamaguchi T, Aukema HM, Kurahashi H, et al. (2012) Global Gene Expression Profiling in PPAR-gamma Agonist-Treated Kidneys in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney Disease. PPAR Res 2012: 695898.
16. Nagao S, Yamaguchi T (2012) PPAR-gamma agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Curr Mol Pharmacol 5: 292-300.
17. Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, et al. (2013) Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. In press.
18. Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS (2013) Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case-Control Study. Drug Saf. In press.
19. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, et al. (2012) The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344: e3645.
20. Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, et al. (2002) The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 30: 259-269.
21. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, et al. (2006) Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227. (Pubitemid 44141912)
22. Sato Y, Harada K, Ozaki S, Furubo S, Kizawa K, et al. (2007) Cholangiocytes with mesenchymal features contribute to progressive hepatic fibrosis of the polycystic kidney rat. Am J Pathol 171: 1859-1871.
23. Whittaker P, Kloner RA, Boughner DR, Pickering JG (1994) Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 89: 397-410.
24. Xue ZF, Wu XM, Liu M (2013) Hepatic regeneration and the epithelial to mesenchymal transition. World J Gastroenterol 19: 1380-1386.
25. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669. (Pubitemid 351615417)
26. Siragy H (1999) Angiotensin II receptor blockers: review of the binding characteristics. Am J Cardiol 84: 3S-8S.
27. Sukumaran V, Watanabe K, Veeraveedu PT, Thandavarayan RA, Gurusamy N, et al. (2010) Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens Res 33: 695-702.
28. Dias NF, Lanzarini V, Onuchic LF, Koch VH (2010) Clinical eyaspects of autosomal recessive polycystic kidney disease. J Bras Nefrol 32: 263-267.
29. Al-Ghamdi H (2011) Carvedilol in the treatment of portal hypertension. Saudi J Gastroenterol 17: 155-158.
30. Schmidt MV, Brune B, von Knethen A (2010) The nuclear hormone receptor PPARgamma as a therapeutic target in major diseases. ScientificWorldJournal 10: 2181-2197.
31. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, et al. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272: 18779-18789. (Pubitemid 27318225)
32. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, et al. (2009) PPARgamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 89: 47-58.
33. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, et al. (2006) PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 350: 385-391. (Pubitemid 44498647)
34. Dai B, Liu Y, Mei C, Fu L, Xiong X, et al. (2010) Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin Sci (Lond) 119: 323-333.
35. Liu Y, Dai B, Xu C, Fu L, Hua Z, et al. (2011) Rosiglitazone inhibits transforming growth factor-beta1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells. PLoS One 6: e28915.
36. Kurtz TW (2005) Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 42 Suppl 1: S9- 16.
37. Tsunenari I, Ohmura T, Seidler R, Chachin M, Hayashi T, et al. (2007) Renoprotective effects of telmisartan in the 5/6 nephrectomised rats. J Renin Angiotensin Aldosterone Syst 8: 93-100. (Pubitemid 47272472)
38. Ohmura T, Tsunenari I, Seidler R, Chachin M, Hayashi T, et al. (2012) Renoprotective effects of telmisartan on renal injury in obese Zucker rats. Acta Diabetol 49 Suppl 1: S15-24.
39. Goyal BR, Parmar K, Goyal RK, Mehta AA (2011) Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats. Pharmacol Rep 63: 956-966.
40. Zong WN, Yang XH, Chen XM, Huang HJ, Zheng HJ, et al. (2011) Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure. Acta Pharmacol Sin 32: 1345-1350.
41. Sipal S, Halici Z, Kiki I, Polat B, Albayrak A, et al. (2012) Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy. J Mol Histol 43: 723-735.
42. Ishizaka N, Saito K, Noiri E, Sata M, Ikeda H, et al. (2005) Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver. Am J Physiol Regul Integr Comp Physiol 288: R1063-1070.
43. Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, et al. (2005) Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 41: 1046-1055. (Pubitemid 40593912)